Citations

Clear

3138 citation(s) found for "Smith, AM".

Pap test and a new biomarker-based technology for enhancing the visibility of abnormal cells
Sundeen, Joseph E., Smith, Wendy M. , Marković, Nataša , Marković, Olivera , Markovic, Svetomir N.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 9561-9561

10.1200/jco.2004.22.90140.9561 Get It

Lack of publication bias in randomized clinical trials (RCTs) sponsored by the National Cancer Institute (NCI) and performed by Cooperative Oncology Groups (COGs)
Daniels, Stephanie, Buckner, Jan C. , Swann, S., Smith, Roy E., Khyatat, A., Wells, Robert J., Djulbegović, Benjamin , Soares, Heloisa P. , Kumar, Ambuj , Daniels, S., Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6004-6004

10.1200/jco.2004.22.90140.6004 Get It

Posterolateral Rotatory Instability of the Elbow: Part I. Mechanism of Injury and the Posterolateral Rotatory Drawer Test
Smith, Jay , O’Driscoll, Shawn W. , O'Driscoll, Shawn W., Camp, Christopher L. , Fitzsimmons, James S

Mayo Clinic

Arthroscopy Techniques | April 3, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1016/j.eats.2016.10.016 | PMID 28580259 Get It

Abstract Posterolateral rotatory instability (PLRI) is the most commonly encountered pattern of elbow instability. It is the result of disruption of the lateral collateral ligament complex leading to a posterolateral rotatory subluxation of the ulna and radial head. A number of examination maneuvers have been described to assist in clinical identification of PLRI. Despite this, some inconsistency in the description of these techniques remains in the orthopaedic literature. This Technical Note details the mechanism of injury and patient presentation, and emphasizes the primacy of the posterolateral rotatory drawer test in the assessment of PLRI while providing video instruction on how it should be performed. Technique Video video See video under supplementary data.
Posterolateral Rotatory Instability of the Elbow: Part II. Supplementary Examination and Dynamic Imaging Techniques
Smith, Jay , O’Driscoll, Shawn W. , O'Driscoll, Shawn W., Camp, Christopher L. , Fitzsimmons, James S

Mayo Clinic

Arthroscopy Techniques | April 3, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1016/j.eats.2016.10.012 | PMID 28580260 Get It

Abstract Currently, a number of examination and imaging techniques exist for diagnosing posterolateral rotatory instability of the elbow. Although the posterolateral rotatory drawer is the primary examination maneuver, other special tests include the lateral pivot‐shift test, prone push‐up test, chair push‐up test, and tabletop push‐up test. In addition, posterolateral rotatory instability can be evaluated using radiography, magnetic resonance imaging, dynamic fluoroscopy, or dynamic ultrasound. In this Technical Note, each of these tests is described in detail. Video instruction is also provided to further explain the techniques and provide examples of positive tests. Technique Video video See video under supplementary data.
Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation.
Florez, Edward , Sirous, Reza , Lirette, Seth T. , Griswold, Michael , Wang, Zhen J. , Bieszczad, Jacob, Cox, Kelly , Goenka, Ajit H. , Howard-Claudio, Candace M, Sanyal, Rupan , Henagen, J. Clark, Storrs, Judd , Allen, Brian C. , Remer, Erick M. , Howard, Candace M. , Kang, HyunSeon Christine , Nandwana, Sadhna B. , Shinagare, Atul Bhanudas , Davenport, Matthew S. , Rini, Brian I. , Smith, Andrew D. , Storrs, Judd M , Lirette, Seth

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 432-432

10.1200/jco.2017.35.6_suppl.432 Get It

432 Background: In clinical trials and clinical practice, tumor response assessment with computed tomography (CT) defines critical end points in patients with metastatic disease treated with systemic agents. Methods to reduce errors and improve efficiency in tumor response assessment could improve patient care. Methods: Eleven readers from 10 different institutions independently categorized tumor response according to three different therapeutic response criteria using paired baseline and initial post-therapy CT studies from 20 randomly selected patients with metastatic renal cell carcinoma treated with sunitinib as part of a completed phase III multi-institutional study. Images were evaluated with a manual tumor response evaluation method (standard-of-care) and with computer-assisted response evaluation (CARE) that included stepwise guidance, interactive error-identification and correction methods, automated tumor metric extraction, calculations, response categorization, and data/image archival. A cross-over design, patient randomization, and two-week washout period were used to reduce recall bias. Comparative effectiveness metrics included error rate and mean patient evaluation time. Results: The standard-of-care method was on average associated with one or more errors in 30.5% (6.1/20) of patients while CARE had a 0.0% (0.0/20) error rate (p<0.001). The most common errors were related to data transfer and arithmetic calculation. In patients with errors, the median number of error types was 1 (range 1-3). Mean patient evaluation time with CARE was twice as fast as the standard-of-care method (6.4 vs. 13.1 minutes, p<0.001). Conclusions: Computer-assisted tumor response evaluation reduced errors and time of evaluation, indicating better overall effectiveness than manual tumor response evaluation methods that are the current standard-of-care.
Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer
Rodriguez‐Broadbent, Henry , Law, Philip , Sud, Amit , Palin, Kimmo , Tuupanen, Sari, Gylfe, Alexandra E., Hänninen, Ulrika A. , Cajuso, Tatiana , Tanskanen, Tomas , Kondelin, Johanna , Kaasinen, Eevi , Sarin, Antti‐Pekka , Rissanen, Harri , Knekt, Paul , Jousilahti, Pekka , Palotie, Aarno , Renkonen‐Sinisalo, Laura , Lepistö, Anna , Böhm, Jan , Mecklin, Jukka‐Pekka , Tassan, Nada Al , Palles, Claire , Martin, Lynn , Barclay, Ella, Farrington, Susan M. , Timofeeva, Maria , Wakil, Salma M. , Campbell, Harry , Idziaszczyk, Shelley, Kaplan, Richard , Kerr, Rachel , Kerr, David , Passarelli, Michael N. , Figueiredo, Jane C. , Buchanan, Daniel D. , Win, Aung Ko , Jenkins, Mark A. , Lindor, Noralane M. , Gallinger, Steven , Conti, David V. , Schumacher, Fredrick R. , Casey, Graham , Aaltonen, Lauri A. , Cheadle, Jeremy P. , Tomlinson, Ian , Dunlop, Malcolm G. , Houlston, Richard S. , Law, Philip J , Buchanan, Daniel D , Win, Aung K , Ripatti, Samuli , Eriksson, Johan G. , Pukkala, ­Eero , Salomaa, Veikko , Palotie, Aarno V. , Meyer, Brian F. , Smith, Christopher G. , Maughan, Tim , Hopper, John L. , Newcomb, Polly A. , Houlston, Richard S , Jenkins, Mark A , Kaplan, Richard , Kerr, Rachel , Palles, Claire , Conti, David V

Mayo Clinic

International Journal of Cancer | March 25, 2017 | Volume: 140 | Issue: 12 | Pages: 2701-2708

10.1002/ijc.30709 | PMID 28340513 Get It

While elevated blood cholesterol has been associated with an increased risk of colorectal cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation (MR) analysis to examine the potential causal relationship between lipid traits and CRC risk. We used single nucleotide polymorphisms (SNPs) associated with blood levels of total cholesterol (TC), triglyceride (TG), low‐density lipoprotein (LDL), and high‐density lipoprotein (HDL) as instrumental variables (IV). We calculated MR estimates for each risk factor with CRC using SNP‐CRC associations from 9,254 cases and 18,386 controls. Genetically predicted higher TC was associated with an elevated risk of CRC (odds ratios (OR) per unit SD increase = 1.46, 95% confidence interval [CI]: 1.20–1.79, p = 1.68 × 10−4). The pooled ORs for LDL, HDL, and TG were 1.05 (95% CI: 0.92–1.18, p = 0.49), 0.94 (95% CI: 0.84–1.05, p = 0.27), and 0.98 (95% CI: 0.85–1.12, p = 0.75) respectively. A genetic risk score for 3‐hydoxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) to mimic the effects of statin therapy was associated with a reduced CRC risk (OR = 0.69, 95% CI: 0.49–0.99, p = 0.046). This study supports a causal relationship between higher levels of TC with CRC risk, and a further rationale for implementing public health strategies to reduce the prevalence of hyperlipidaemia.
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Gonçalves, Priscila , Heilbrun, Lance K. , Barrett, Michael T. , Hansen, Aaron R. , Sukari, Ammar , Smith, Daryn , Casetta, Lindsay, Boerner, Scott A. , Chen, Alice P. , Lenkiewicz, Elizabeth, Malasi, Smriti, LoRusso, Patricia , Kummar, Shivaani , Siu, Lillian L. , Piekarz, Richard , Chao, Joseph , Pilat, Mary Jo , Hansen, Aaron R

Mayo Clinic

Oncotarget | March 22, 2017 | Volume: 8 | Issue: 20 | Pages: 32918-32929

10.18632/oncotarget.16464 | PMID 28415633 Get It

Proton beam therapy for liver cancer is well tolerated: Outcomes from the Proton Collaborative Group REG001-09 trial.
Chuong, Michael D. , Hartsell, William F. , Larson, Gary, Rossi, Carl J., Vargas, Carlos , Apisarnthanarax, Smith , Tsai, Henry K.

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 389-389

10.1200/jco.2017.35.4_suppl.389 Get It

389 Background: The liver is one of the most radiosensitive organs, making radiation therapy (RT) for liver tumors extremely challenging. RT is appropriate only for a minority of liver patients with limited tumor burden; a reduction in the prescribed radiation dose may be needed to lower the probability of radiation-induced liver disease especially in the presence of cirrhosis. Proton beam therapy (PBT) delivers less dose to the liver than photon therapy and is expected to reduce toxicity while also permitting safe dose escalation for some patients with liver tumors. Methods: The Proton Collaborative Group REG001-09 trial (NCT01255748) prospectively collects data for PBT patients with a variety of cancer types. To better understand treatment details and outcomes associated with liver PBT, patients enrolled on the PCG registry trial from 5 institutions who received liver PBT for any cancer between 2012 and 2016 were analyzed. Results: A total of 43 liver cancer patients were included, most with hepatocellular carcinoma (48.8%) or cholangiocarcinoma (25.6%). The vast majority did not have surgery at any time (86%). Most were treatment naive prior to PBT; 2 previously had RT and 8 had prior chemotherapy (mostly cholangiocarcinoma patients). The median total prescribed PBT dose was 58.05 Gy(RBE) (range 21.7-67.5). The median number of prescribed fractions was 15 (range 12-37). PBT was delivered to only the liver in 90.7% of patients; inclusion of lymph nodes was rare. Uniform scanning was used in 26 (72.1%) and pencil beam scanning in 2 patients (4.7%); the delivery technique used for the remaining patients was unknown (23.2%). With median follow up of 4.4 months (range 1.3-17.9), 3 patients (7%) had an intrahepatic recurrence, 2 patients (4.6%) developed distant metastasis, and 10 patients (23.3%) died. No grade 3 or higher toxicity was reported although 17 patients (39.5%) had grade 2 toxicity predominantly fatigue, anorexia, nausea, or vomiting. Conclusions: Although longer follow up is needed to assess late toxicities as well as disease control, early outcomes from the PCG registry trial for liver cancer patients shows that predominantly hypofractionated PBT has a very favorable acute toxicity profile.
Cyclosporine: A Historical Perspective on Its Role in the Treatment of Noninfectious Uveitis
Smith, Wendy M.

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | March 13, 2017 | Volume: 33 | Issue: 4 | Pages: 247-262

10.1089/jop.2016.0155 | PMID 28287852 Get It

Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy
Higgins, Erin M. , Bos, J. Martijn , Mason‐Suares, Heather , Tester, David J. , Ackerman, Jaeger P., MacRae, Calum A. , Sol‐Church, Katia, Gripp, Karen W. , Ackerman, Michael J. , Urrutia, Raúl , Bos, Johan M

Mayo Clinic

JCI Insight | March 8, 2017 | Volume: 2 | Issue: 5 | Pages: No page available

10.1172/jci.insight.91225 | PMID 28289718 Get It

Noonan syndrome (NS; MIM 163950) is an autosomal dominant disorder and a member of a family of developmental disorders termed “RASopathies,” which are caused mainly by gain-of-function mutations in genes encoding RAS/MAPK signaling pathway proteins. Whole exome sequencing (WES) and trio-based genomic triangulation of a 15-year-old female with a clinical diagnosis of NS and concomitant cardiac hypertrophy and her unaffected parents identified a de novo variant in MRAS -encoded RAS-related protein 3 as the cause of her disease. Mutation analysis using in silico mutation prediction tools and molecular dynamics simulations predicted the identified variant, p.Gly23Val-MRAS, to be damaging to normal protein function and adversely affect effector interaction regions and the GTP-binding site. Subsequent ectopic expression experiments revealed a 40-fold increase in MRAS activation for p.Gly23Val-MRAS compared with WT-MRAS. Additional biochemical assays demonstrated enhanced activation of both RAS/MAPK pathway signaling and downstream gene expression in cells expressing p.Gly23Val-MRAS. Mutational analysis of MRAS in a cohort of 109 unrelated patients with phenotype-positive/genotype-negative NS and cardiac hypertrophy yielded another patient with a sporadic de novo MRAS variant (p.Thr68Ile, c.203C>T). Herein, we describe the discovery of mutations in MRAS in patients with NS and cardiac hypertrophy, establishing MRAS as the newest NS with cardiac hypertrophy-susceptibility gene.